MedPath

Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Clinical Trials
Related News

Hawaii Secures $700 Million Settlement from Bristol Myers Squibb and Sanofi Over Plavix Efficacy in Diverse Populations

• Hawaii will receive $700 million from Bristol Myers Squibb and Sanofi following litigation over blood thinner Plavix's reduced efficacy in Asian American, Pacific Islander, and Native Hawaiian populations. • The settlement resolves a 13-year legal battle where the state accused the pharmaceutical companies of failing to warn that Plavix could be ineffective in certain ethnic groups, with the medication prescribed over 837,000 times in Hawaii between 1998-2010. • The case highlights critical concerns about pharmaceutical companies' consideration of ethnic and genetic diversity in drug development, potentially setting precedent for similar cases in jurisdictions with diverse populations.

NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry

• India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin. • The price regulations follow the March 11, 2025 expiry of Boehringer Ingelheim's empagliflozin patent, opening the market to multiple pharmaceutical companies including Mankind Pharma, Lupin, and Alkem Laboratories. • Beyond diabetes medications, the NPPA's pricing decisions also cover anti-hypertensive combinations containing telmisartan and metoprolol, as well as anti-inflammatory formulations with paracetamol and mefenamic acid.

2025 Pharmaceutical Pipeline: Major Patent Expirations Set to Transform Drug Market with Generics and Biosimilars

• The US pharmaceutical market is poised for significant change in 2025 as several blockbuster drugs including Xarelto, Entresto, and Stelara face patent expirations, opening the door to generic and biosimilar competition. • Multiple biosimilars for ustekinumab (Stelara) are entering the market in 2025, with Wezlana already launched in January as the first interchangeable biosimilar, while other major drugs like ticagrelor and denosumab will also face competition. • The pharmaceutical pipeline continues to expand with innovative therapies for cancer and neurological disorders, alongside the Medicare Drug Price Negotiation program which will further impact pricing dynamics for high-cost medications.

Helix Research Network Reveals Genomic Screening Improves Patient Care and Risk Identification at ACMG 2025

• Helix's population genomics research demonstrates that genomic screening accurately identifies high-risk individuals and improves adherence to recommended care protocols across multiple conditions. • The Helix Research Network, North America's largest precision clinical research network, presented findings showing improved clinical management for conditions including familial hypercholesterolemia and hereditary breast cancer. • Real-world evidence from Helix's multi-health system studies reveals automated variant interpretation achieves accuracy equivalent to standard ACMG/AMP guidelines, potentially streamlining genetic testing implementation.

Novel Anti-Platelet Drug AT-10 Shows Promise in Overcoming Clopidogrel Resistance

• A Phase 1 study demonstrates that AT-10, a novel anti-platelet agent, effectively overcomes the genetic limitations of clopidogrel in both poor and extensive metabolizers of CYP2C19. • AT-10 achieved significantly higher platelet inhibition compared to clopidogrel across all patient groups, with superior pharmacokinetic profiles in both single and multiple dose regimens. • The drug showed a favorable safety profile with minor adverse events, potentially offering a more reliable alternative to clopidogrel for patients with cardiovascular conditions.

Intravenous Urokinase vs Best Medicine Treatment for Acute Ischemic Stroke: A Comparative Study

A recent study compared the efficacy and safety of intravenous urokinase (UK) with guideline-based best medicine treatment for acute ischemic stroke patients. Conducted across 25 hospitals in China, the TRUST trial aimed to assess functional outcomes, with a focus on patients treated within 6 hours of symptom onset. The study found that UK treatment could potentially offer better functional outcomes, though it also highlighted the importance of careful patient selection due to the risk of symptomatic intracranial hemorrhage.

Landmark Ticagrelor Trial Faces Renewed Scrutiny Over Data Integrity

• A _BMJ_ investigation raises concerns about the PLATO trial, which supported the approval of ticagrelor, citing issues in data reporting and accuracy. • The FDA approved ticagrelor despite internal objections regarding the reliability of PLATO trial data, particularly concerning outcomes in US patients. • Subsequent studies have struggled to replicate PLATO's positive results, leading to calls for a reappraisal of ticagrelor's role in clinical guidelines. • Discrepancies in death records and endpoint adjudication, along with potential conflicts of interest, further fuel the controversy surrounding the trial's validity.

Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised

• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million. • Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth. • The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS. • Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.

Bristol-Myers Squibb: 150 Years of Pharmaceutical Innovation and Global Healthcare Leadership

• Bristol-Myers Squibb, founded in 1858, has evolved from a small Brooklyn pharmaceutical company to a global healthcare leader with approximately 28,000 employees and focus on six core therapeutic areas. • The company's landmark merger in 1989 created a pharmaceutical powerhouse with combined profits of $1.3 billion, leading to over 60 product lines generating $50+ million in annual sales by 1995. • BMS maintains a robust pipeline with 40 compounds in exploratory development and 6 in late-stage development, despite facing patent expiration challenges for key drugs like Plavix and Avapro.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy